A Comparative Review of the Lipoglycopeptides: Oritavancin, Dalbavancin, and Telavancin

In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria

(2008) K. M. Krause et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Telavancin Penetration into Human Epithelial Lining Fluid Determined by Population Pharmacokinetic Modeling and Monte Carlo Simulation

(2008) T. P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States

(2008) D. C. Draghi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against Staphylococcus aureus

(2008) A. Belley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms

(2008) Martin E. Stryjewski et al.   CLINICAL INFECTIOUS DISEASES

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

(2008) Helen W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

A new lipoglycopeptide: telavancin

(2008) Esteban C Nannini et al.   EXPERT OPINION ON PHARMACOTHERAPY

Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects

(2008) S. L. Wong et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY